Jump to content

Noribogaminalog

Add links
From Wikipedia, the free encyclopedia
(Redirected from Substituted ibogalog)
Noribogaminalog
Names
IUPAC name
1,2,3,4,5,6-Hexahydroazepino[4,5-b]indole
Other names
N-Desmethylibogaminalog
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
EC Number
  • 982-798-9
  • InChI=1S/C12H14N2/c1-2-4-11-9(3-1)10-5-7-13-8-6-12(10)14-11/h1-4,13-14H,5-8H2
    Key: NGUNYFTXLWTSNC-UHFFFAOYSA-N
  • C1CNCCC2=C1C3=CC=CC=C3N2
Properties
C12H14N2
Molar mass 186.258 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Noribogaminalog, or N-desmethylibogaminalog, also known as 1,2,3,4,5,6-hexahydroazepino[4,5-b]indole, is a chemical compound and parent structure of the ibogalog group of compounds.[1][2][3] The ibogalogs that have been described include ibogaminalog, ibogainalog, noribogainalog, tabernanthalog, fluorogainalog, LS-22925, PNU-22394, and PHA-57378, among others.[1][2][3][4][5]

See also

[edit]

References

[edit]
  1. ^ a b Tae HS, Ortells MO, Tekarli BJ, Manetti D, Romanelli MN, McIntosh JM, Adams DJ, Arias HR (July 2023). "DM506 (3-Methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole fumarate), a Novel Derivative of Ibogamine, Inhibits α7 and α9α10 Nicotinic Acetylcholine Receptors by Different Allosteric Mechanisms". ACS Chem Neurosci. 14 (14): 2537–2547. doi:10.1021/acschemneuro.3c00212. PMID 37386821.
  2. ^ a b Sutton C, Williams EQ, Homsi H, Beerepoot P, Nazari R, Han D, Ramsey AJ, Mash DC, Olson DE, Blough B, Salahpour A (2022). "Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones". Front Cell Neurosci. 16: 832536. doi:10.3389/fncel.2022.832536. PMC 9124866. PMID 35614973.
  3. ^ a b Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, Rabow ZT, Fiehn O, Wulff H, McCorvy JD, Lein PJ, Kokel D, Ron D, Peters J, Zuo Y, Olson DE (January 2021). "A non-hallucinogenic psychedelic analogue with therapeutic potential". Nature. 589 (7842): 474–479. Bibcode:2021Natur.589..474C. doi:10.1038/s41586-020-3008-z. PMC 7874389. PMID 33299186.
  4. ^ Jensen AA, Plath N, Pedersen MH, Isberg V, Krall J, Wellendorph P, Stensbøl TB, Gloriam DE, Krogsgaard-Larsen P, Frølund B (February 2013). "Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT(2A)/5-HT(2C) receptor agonists with pro-cognitive properties". J Med Chem. 56 (3): 1211–1127. doi:10.1021/jm301656h. PMID 23301527.
  5. ^ Ennis MD, Hoffman RL, Ghazal NB, Olson RM, Knauer CS, Chio CL, Hyslop DK, Campbell JE, Fitzgerald LW, Nichols NF, Svensson KA, McCall RB, Haber CL, Kagey ML, Dinh DM (July 2003). "2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists". Bioorg Med Chem Lett. 13 (14): 2369–2372. doi:10.1016/s0960-894x(03)00403-7. PMID 12824036.
[edit]



Stub icon

This article about an organic compound is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Noribogaminalog&oldid=1292981826"